1. [Patient with type II membranoproliferative glomerulonephritis: intravitreal bevacizumab therapy for choroidal neovascularization].
- Author
-
Karampelas M, Kopsachilis N, Chang JH, and Pal B
- Subjects
- Adult, Angiogenesis Inhibitors administration & dosage, Bevacizumab, Choroidal Neovascularization etiology, Glomerulonephritis, Membranoproliferative complications, Humans, Intravitreal Injections, Male, Treatment Outcome, Antibodies, Monoclonal, Humanized administration & dosage, Choroidal Neovascularization drug therapy, Choroidal Neovascularization pathology, Glomerulonephritis, Membranoproliferative drug therapy, Glomerulonephritis, Membranoproliferative pathology
- Abstract
Membranoproliferative glomerulonephritis (MPGN) type II is a rare disease characterized by electron dense deposits on the basement membrane in the glomeruli of the kidneys and also in Bruch's membrane of the eye. Although most patients have asymptomatic drusen of the retina choroidal neovascularization can sometimes develop, which can permanently affect visual acuity. We report an unusual case of choroidal neovascularization in a patient with MPGN type II that was successfully treated with a single intravitreal injection of bevacizumab. The 6 months follow-up showed no recurrence of choroidal neovascularization.
- Published
- 2012
- Full Text
- View/download PDF